Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
178 stopped studies mapped to Triple-Negative Breast Carcinoma and descendants · 97% state a reason
Over the 178 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic…(BATON-BC) | Phase 2 | terminated | Dec 10, 2012 | AVEO Pharmaceuticals, Inc. | low enrollment | Enrollment / accrual |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | Phase 2 | withdrawn | Nov 4, 2019 | AHS Cancer Control Alberta | Sponsor withdrew support | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03777579 | A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in… | Phase 3 | suspended | Dec 17, 2018 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | trial handovered to another sponser. | Other (stated, no rule matched) |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Phase 1 | terminated | Mar 5, 2014 | Pfizer | The study was terminated due to a change in sponsor prioritization. | Other (stated, no rule matched) |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable… | Phase 2 | withdrawn | Aug 23, 2018 | University of Washington | No participants enrolled. | Enrollment / accrual |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without… | Phase 2 | terminated | Nov 24, 2014 | Pfizer | The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development.… | Safety / toxicity |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or…(VICTOR3) | Phase 2 | terminated | Nov 30, 2017 | Mario Negri Institute for Pharmacological Research | Low accrual rate | Enrollment / accrual |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT03045393 | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC(IMGN853) | Phase 1 | withdrawn | Feb 7, 2017 | Duke University | Inadequate enrollment | Enrollment / accrual |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02365662 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced… | Phase 1 | terminated | Feb 19, 2015 | AbbVie | Safety | Safety / toxicity |
| NCT01319539 | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | Phase 2 | terminated | Mar 21, 2011 | National Cancer Institute (NCI) | terminated early, due to toxicity | Safety / toxicity |
| NCT01918306 | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple… | Phase 1 / Phase 2 | terminated | Aug 7, 2013 | Vanderbilt-Ingram Cancer Center | company stopped production of study drug due to excessive toxicities, lack of efficacy | Safety / toxicity |
| NCT01936961 | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid…(I-CREST) | N/A | withdrawn | Sep 6, 2013 | Western Regional Medical Center | No patients enrolled | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | Jun 28, 2010 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple-… | Phase 2 | withdrawn | Feb 18, 2016 | Peregrine Pharmaceuticals | not stated | Not stated |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously… | Phase 1 / Phase 2 | withdrawn | Jan 22, 2016 | Case Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast… | Phase 2 | withdrawn | Sep 2, 2015 | First Affiliated Hospital Xi'an Jiaotong University | because of safety problem, this trial was stopped in the hospital | Safety / toxicity |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced… | Phase 1 | withdrawn | Dec 11, 2015 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin… | Phase 1 | terminated | Nov 10, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01071564 | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or… | Phase 1 | terminated | Feb 19, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01292083 | Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer… | N/A | withdrawn | Feb 9, 2011 | University of Southern California | No accrual last 2 years | Enrollment / accrual |
| NCT01695057 | Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer | N/A | withdrawn | Sep 27, 2012 | University of Southern California | Lack of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 27, 2020source: clinicaltrials